Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00622063
NCT00622063CompletedPhase 1

An Extension Study for Patients Previously Treated With ARQ 501

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)2 sites in 1 country1 target enrollmentStarted: December 1, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
1
Locations
2
Primary Endpoint
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Signed written informed consent
  • •Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment

Exclusion Criteria

  • •Have not received previous treatment with ARQ 501 under a treatment protocol
  • •Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

Outcomes

Primary Outcomes

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Time Frame: No time frame

Secondary Outcomes

  • To collect additional safety and tolerability information for ARQ 501 treatment(No time frame)

Investigators

Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Terminated
Phase 1
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Gliomas, MalignantGlioblastoma MultiformeAstrocytoma
NCT04327011Tocagen Inc.65
Completed
Phase 1
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsAdvanced Solid Tumors
NCT01178411ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)60
Recruiting
Not Applicable
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesBreast CancerLung CancerColon CancerLiver CancerProstate Cancer
NCT00451022National Cancer Institute (NCI)750
Terminated
Phase 2
An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311Alzheimer's Disease
NCT03531710United Neuroscience Ltd.34
Completed
Phase 2
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCancer
NCT04125693Bayer1
An Extension Study for Patients Previously... | Clinical Trial